Leeper, Nicholas J.

CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis

Kojima, Y., Volkmer, J.-P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., Direnzo, D., Nanda, V., Ye, J., Connolly, A. J., et al. (2016) · Nature

Phagocytosis and Immune RegulationAtherosclerosis and Cardiovascular Diseases

Cited by 683

The role of efferocytosis in atherosclerosis

Kojima, Y., Weissman, I. L., & Leeper, N. J. (2017) · Circulation

Phagocytosis and Immune RegulationAtherosclerosis and Cardiovascular Diseases

Cited by 289

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia

Ballantyne, C. M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R. S., Chang, T., Melquist, S., Zhou, R., Mushin, M., Leeper, N. J., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 210

Stem Cell Therapy for Vascular Regeneration: Adult, Embryonic, and Induced Pluripotent Stem Cells

Leeper, N. J., Hunter, A. L., & Cooke, J. P. (2010) · Circulation

Mesenchymal stem cell researchAngiogenesis and VEGF in Cancer

Cited by 195

Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk

Watts, G. F., Rosenson, R. S., Hegele, R. A., Goldberg, I. J., Gallo, A., Mertens, A., Baass, A., Zhou, R., Muhsin, M., Hellawell, J., et al. (2025) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 178

Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis

Kojima, Y., Downing, K., Kundu, R., Miller, C., Dewey, F., Lancero, H., Raaz, U., Perisic, L., Hedin, U., Schadt, E., et al. (2014) · Journal of Clinical Investigation

Atherosclerosis and Cardiovascular DiseasesPhagocytosis and Immune Regulation

Cited by 148